Ultragenyx Pharmaceutical Inc  

(Public, NASDAQ:RARE)   Watch this stock  
Find more results for RARE
47.84
-0.27 (-0.56%)
After Hours: 47.84 0.00 (0.00%)
Nov 20, 4:57PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 47.10 - 48.26
52 week 44.02 - 91.35
Open 48.11
Vol / Avg. 223,109.00/441,938.00
Mkt cap 2.04B
P/E     -
Div/yield     -
EPS -6.97
Shares 42.59M
Beta 1.81
Inst. own 98%
Feb 14, 2018
Q4 2017 Ultragenyx Pharmaceutical Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Dec 4, 2017
Ultragenyx Pharmaceutical Inc Analyst Day - 8:00AM EST - Add to calendar
Nov 15, 2017
Ultragenyx Pharmaceutical Inc to Discuss MEPSEVII FDA Approval - Call - Webcast
Nov 15, 2017
Ultragenyx Pharmaceutical Inc at Stifel Healthcare Conference
Nov 8, 2017
Ultragenyx Pharmaceutical Inc at Credit Suisse Healthcare Conference - Webcast
Nov 2, 2017
Q3 2017 Ultragenyx Pharmaceutical Inc Earnings Call - Webcast
Nov 2, 2017
Q3 2017 Ultragenyx Pharmaceutical Inc Earnings Release
Sep 18, 2017
Ultragenyx Pharmaceutical Inc to Acquire all of the Outstanding Shares of Common Stock of Dimension Therapeutics, Inc. M&A Call - Webcast
Sep 12, 2017
Ultragenyx Pharmaceutical Inc at Morgan Stanley Healthcare Conference - Webcast
Sep 7, 2017
Ultragenyx Pharmaceutical Inc at Robert W Baird Gobal Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -40013.64% -184867.70%
Operating margin -42279.29% -186471.40%
EBITD margin - -183897.00%
Return on average assets -68.15% -44.70%
Return on average equity -79.94% -48.93%
Employees 376 -
CDP Score - -

Address

60 Leveroni Ct
NOVATO, CA 94949-5746
United States - Map
+1-415-4838800 (Phone)
+1-415-4838810 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies. Its product candidates under biologics category include KRN23 (UX023) and recombinant human beta-glucuronidase (rhGUS) (UX003). Its product candidates under small-molecule category include UX007 and aceneuramic acid extended-release (Ace-ER) (UX001). It is also developing recombinant human protective protein cathepsin-A (rhPPCA). KRN23 is a fully human monoclonal antibody. rhGUS is an intravenous (IV) enzyme replacement therapy. UX007 is a substrate replacement therapy. It is developing Ace-ER for the treatment of GNE myopathy. rhPPCA is in preclinical development.

Officers and directors

Daniel G. Welch Independent Chairman of the Board
Age: 59
Bio & Compensation  - Reuters
Emil D. Kakkis M.D. Ph.D. President, Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Shalini Sharp Chief Financial Officer, Executive Vice President
Age: 42
Bio & Compensation  - Reuters
Sunil Agarwal M.D. President - Research and Development
Age: 47
Bio & Compensation  - Reuters
Karah Parschauer Executive Vice President, General Counsel
Age: 39
Bio & Compensation  - Reuters
Jayson Dallas M.D. Chief Commercial Officer and Executive Vice President
Age: 49
Bio & Compensation  - Reuters
Dennis Karl Huang Chief Technical Operations Officer, Executive Vice President
Age: 52
Bio & Compensation  - Reuters
Thomas Kassberg Chief Business Officer, Executive Vice President
Age: 56
Bio & Compensation  - Reuters
John R. Pinion II Chief Quality Operations Officer and Executive Vice President Analytical Sciences and Research
Age: 51
Bio & Compensation  - Reuters
William E. Aliski Independent Director
Age: 69
Bio & Compensation  - Reuters